MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

0.42 -6.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.42

Max

0.46

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+877.78% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-12M 94M
Eelmine avamishind	7.09
Eelmine sulgemishind	0.42

Uudiste sentiment

By Acuity

70%

30%

322 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First Quarter Net Rose On Strong Demand

15. apr 2026, 17:13 UTC

Suurimad hinnamuutused turgudel

Tesla Shares Rise on Completion of AI5 Chip Design Process

15. apr 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15. apr 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15. apr 2026, 22:41 UTC

Tulu

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15. apr 2026, 22:38 UTC

Tulu

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15. apr 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. apr 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15. apr 2026, 22:14 UTC

Tulu

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15. apr 2026, 22:12 UTC

Tulu

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology Swings to Loss in 1Q>300433.SZ

15. apr 2026, 22:07 UTC

Tulu

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15. apr 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15. apr 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15. apr 2026, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. apr 2026, 20:30 UTC

Tulu

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. apr 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15. apr 2026, 19:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15. apr 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15. apr 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15. apr 2026, 18:58 UTC

Market Talk

Uudisväärsed sündmused

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15. apr 2026, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15. apr 2026, 17:45 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15. apr 2026, 16:58 UTC

Tulu

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15. apr 2026, 16:52 UTC

Tulu

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15. apr 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15. apr 2026, 16:37 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

877.78% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 877.78%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

322 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.